NEW YORK (GenomeWeb News) – SDIX reported after the close of the market on Thursday a 15 percent falloff year over year in first-quarter revenues.

The company also announced a deal with a top-10 drug firm to generate monoclonal antibodies against a GPCR target.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.